{Title}

China Healthcare Summit | 2019

BioCentury and BayHelix Present: The 6th China Healthcare Summit



November 18 - 20, 2019 | Shanghai

LOCATION

Jing An Shangri-La, Shanghai

PRICING AND CHINA ENTREPRENEUR RATE INFORMATION

1. Registration: $1,400 or CNY9,415
2. Registration for BayHelix/PhIRDA/RDPAC members: $1,200 or CNY8,075
3. China Entrepreneur Registration: $500 or CNY3,375

The China Entrepreneur rate is subject to approval. Those eligible include founders and senior management of China-based healthcare startups in the products and services space. This rate excludes consultants, advisors, investors and multinational companies. There is a limit of two registrations per company at this rate. To request this rate, please email kevin@biocentury.com.


China In The World: A program focused on what China must do to stand alongside the world’s leaders in the innovation ecosystem.

Six years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2019, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts.

The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting.

The China Summit agenda is developed by an Organizing Committee that includes China industry KOLs and the BioCentury editorial team. Simultaneous translation is provided in all strategic sessions.

Highlights include:

Strategic Sessions: 2 days of tailored content to help busy executives understand emerging opportunities and challenges in China.

Exclusive Report: The China Summit report created by Insights Partner, McKinsey & Company. This exclusive analysis documents market trends and identifies business imperatives for biopharma and life sciences companies doing business in China.

Road Show Presentations: Includes 30+ biotechs from China, Asia and the West, hand-picked by BioCentury and BayHelix.

1x1 Meeting System: Attendees can arrange face-to-face discussions with investors and corporate delegates over 2 full days.

BayHelix Awards Lunch Banquet: An annual celebration of R&D and commercial achievements in China.

VIP Receptions: Network with senior-level executives and investors at the Monday night Welcome Reception and the Gala Dinner on Tuesday.

The China Summit agenda is developed by an Organizing Committee that includes China industry KOLs and the BioCentury editorial team. Simultaneous translation is provided in all strategic sessions.

Hotel accommodations: The conference hotel block at Jing An Shangri-La (conference venue) for attendees of the China Summit is sold out. For questions related to hotel options, please contact Louisa Chen, our local conference organizer, at louisa.chen@lycheegroup.com.

Building Bridges to Innovation - The China Healthcare Summit Report by McKinsey & Company

Download the 2018 Report
Download the 2017 Report
Download the 2016 Report
Download the 2015 Report


Return to Conferences List
SCHEDULE
Monday, November 18, 2019

1:00 PM  to  1:30 PM
Conference Registration & Networking
Shanghai Jing An Shangri-La (3rd Floor)
1:30 PM  to  3:30 PM
C-Suite Clinical Development Bootcamp (included in conference registration)
Magnolia Ballroom 1 (3rd Floor)
Success in finding strategic partners and winning regulatory approval hinges on crucial product development decisions, beginning at discovery. The hurdles are becoming even more complicated as regulators are quickly adopting new endpoints, clinical designs and new statistics to address today’s complex new products. This session is especially tailored for Chinese executives who are responsible for make-or-break decisions years before their product ever reach the patient. The Bootcamp is divided into three parts: Regulatory, Early Development and Clinical Operations.

Session Chair:
• Lingshi Tan, Ph.D., Founder & CEO, dMed Biopharmaceutical Co. Ltd.

Featuring:
• Wenyu GUO, M.D., VP, Clinical Operations, CStone Pharmaceuticals Co. Ltd.
• Min Irwin, Ph.D., CEO, Reistone Biopharma Co. Ltd.
• Helen Qinghong LI, M.D., Head, Medical Quality Assurance, China, Pfizer Inc.
• Yi LIU, VP, Clinical Science & Medical Affairs, dMed Biopharmaceutical Co. Ltd.
• Chris Lu, Ph.D., Founder & CEO, Laekna Therapeutics Shanghai Co. Ltd.
• Joan Shen, M.D., CEO, I-Mab Biopharma Co. Ltd.
• Jun SHI, M.D., SVP, Early Development & Clinical Pharmacology, dMed Biopharmaceutical Co. Ltd.
• Angela Yan, SVP, Regulatory Affairs & Strategy, dMed Biopharmaceutical Co. Ltd.
• Peiyng YAO, Executive Director, Quality Assurance, dMed Biopharmaceutical Co. Ltd.
• Eric Zhang, Ph.D., VP, Regulatory Affairs & Strategy, dMed Biopharmaceutical Co. Ltd.

3:30 PM  to  4:00 PM
Networking Break
Shanghai Jing An Shangri-La
4:00 PM  to  6:00 PM
C-Suite Communications Bootcamp (included in conference registration)
Magnolia Ballroom 1 (3rd Floor)
Beyond geopolitics, Chinese biopharma executives share a common challenge with their peers inside the U.S.: How to deal with unrelenting demands for information, transparency and access to investors, regulators, partners, the public and the media. This session is especially tailored for Chinese executives who must successfully communicate with all these stakeholders in order to become global players.

Hosted by Brunswick Group, Sidley & Austin LLP, BioCentury and BayHelix

Session Chairs:
• Ruchun JI, Partner, Sidley Austin LLP
• ZHOU Yi, Director, Brunswick Group LLP

Featuring:
• Karen Bernstein, Ph.D., Chairman, BioCentury Inc.
• Lanhee Chen, Ph.D., Senior Counselor, Brunswick LLP
• Meng DING, Partner, Sidley Austin LLP
• Vijay Karwal, Head of Healthcare Investment Banking, Asia ex-Japan, Nomura
• Derrick Li, Head of Strategy & Investor Relations, Cellular Biomedicine Group
• Judith Li, Partner, Lilly Asia Ventures
• Joseph Chi Lo, Partner, Brunswick Group LLP
• St. John Moore, Partner & Head of Beijing, Brunswick Group LLP
• Dongxu QIU, Ph.D., Co-Founder & Executive VP, Strategy and Business Development, CanSino Biologics Inc.

6:00 PM  to  9:00 PM
Welcome Reception
Shanghai Jing An Shangri-La, Lifestyle Suite & Garden (4th Floor)
Network with biotech C-suite executives and investors from China, Asia and the West.

Hosted by Pivotal China BioVenture, Nan Fung Life Sciences, BioCentury and BayHelix
Tuesday, November 19, 2019

7:45 AM  to  8:50 AM
Conference Registration & Breakfast Networking
Shanghai Jing An Shangri-La (5th Floor)
Hosted by CEC Capital, BioCentury and BayHelix
8:50 AM  to  9:00 AM
Welcoming Remarks
• David Flores, President & CEO, BioCentury
• Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc.

9:00 AM  to  9:50 AM
Blue Ribbon Panel: China In The World
Ballroom 1 (5th Floor)
To provide context for the entire conference, BioCentury and BayHelix convene a special Blue Ribbon Panel to debate the challenges China must address to stand alongside the world’s leaders in the innovation ecosystem.

Session Chairs:
• Karen Bernstein, Ph.D., Chairman, BioCentury Inc.
• Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc.

Featuring:
• Li CHEN, Ph.D., Founder & CEO, Hua Medicine Ltd.
• Joe Damond, EVP, International Affairs, BIO (Biotechnology Innovation Organization)
• Tao FU, President & Chief Operating Officer, Zai Lab Ltd.
• James Mendenhall, Partner, Sidley Austin LLP and former General Counsel, Office of the United States Trade Representative
• Graziano Seghezzi, Managing Partner, Sofinnova Partners
• Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd.

9:50 AM  to  10:20 AM
Fireside Chat – IP Reforms In China
Ballroom 1 (5th Floor)
Intellectual property rules like patent linkage and data exclusivity have been pivotal to the growth of biotechnology in the West. But China’s blueprint for IP reform remains stalled. In this rare discussion, the former chief judge of the U.S. patent court and the former senior judge of the IP Division of the Beijing People's Court describe how unlocking these reforms will enable China’s innovators to compete on a level playing field with their Western peers.

Moderator:
• Tony Chen, Partner, Jones Day

Featuring:
• Yongshun CHENG, Director, Beijing Intellectual Property Institute, and former Senior Judge, IP Division, Beijing High People’s Court
• Randall Rader, Principal, The Rader Group, and former Chief Judge, U.S. Court of Appeals for the Federal Circuit
10:20 AM  to  10:50 AM
Morning Networking Break
Hosted by CEC Capital, BioCentury and BayHelix
10:30 AM  to  12:30 PM
Presenting Companies: China Biotech Track (Session 1)
Ballroom 2 (5th Floor)
Hosted by BeiGene Ltd., BioCentury and BayHelix

10:30am-10:45am BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160)

10:45-11am Hua Medicine Ltd. (HKSE:2552)

11am-11:15am Transcenta Holding Ltd.

11:15am-11:30am EOC Pharma Group

11:30am-11:45am Impact Therapeutics Inc.

11:45am-12pm Yisheng Biopharma Co. Ltd.

12pm-12:15pm Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

12:15pm-12:30pm AffaMed Therapeutics

10:50 AM  to  11:40 AM
4TH ANNUAL CSO/CMO ROUNDTABLE
Ballroom 1 (5th Floor)
The Summit's 4th Annual Heads of Research Roundtable is expanding this year to include CMOs, as we analyze how far China’s R&D leaders and scientist-CEOs have come along the innovation pathway, and what challenges they must conquer – from science to talent to clinical development – to enable their companies to stand alongside the world's leaders in the creation of novel products that address profound patient needs.

Session Chair:
• Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec

Featuring:
• Yong Ben, M.D. Chief Medical Officer, Immuno-Oncology, BeiGene Ltd.
• Hongtao LU, Ph.D., Co-Founder, Chief Scientific Officer & Director, Elpiscience Biopharmaceuticals Co. Ltd.
• Sophie Sun, Managing Director, Innovation Hub China & VP, Strategy and Transformation, China, Merck Holding (China) Co. Ltd.
• Zaiqi WANG, Ph.D., Founder & CEO, InxMed Shanghai
• Lei XIAO, Ph.D., Chairman, CEO & Chief Scientific Officer, Innovative Cellular Therapeutics Co. Ltd.

10:50 AM  to  11:30 AM
3rd Annual Healthcare AI/Precision Medicine Showcase (Part 1) – Where Digital Health Meets Personalized Medicine
Ballroom 3 (5th Floor)
Precision medicine arguably won’t be realized without advances in the areas of digital health that most directly affect patients – digital therapeutics, digital diagnostics and digital disease management tools. First movers and early adopters include U.S. FDA, multinational pharmas and venture-backed innovator start-ups. But it is still early days. Can China leverage its prowess in AI and machine learning to lead in the effort to create digital health products globally?

Session Chair:
• Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury

Featuring:
• Yuzhong CHEN, M.D., Chief Medical Officer & VP, Airdoc
• Yiming HAO, General Manager, Innovative Commercialization Solutions, HLT
• Irene Hong, Founding Partner, CEC Capital
• Tony Zhang, Founder & CEO, LinkDoc Technology (Beijing) Co.
• Hao ZOU, Ph.D., CEO, Tsimage Technology, and Director, Center for Medical Imaging and Health, Tsinghua University

11:30 AM  to  12:10 PM
3rd Annual Healthcare AI/Precision Medicine Showcase (Part 2) – Drug Discovery
Ballroom 3 (5th Floor)
Artificial intelligence is rapidly propagating into drug discovery. In this third year of the AI/Precision Medicine Showcase, this panel of data scientists reviews what has China accomplished in AI and machine-learning that will affect the speed and effectiveness of the global discovery engine, and identify the next frontiers at the intersection of data and biology.

Session Chair:
• Weiyi ZHANG, Director, External Innovation China, Boehringer Ingelheim GmbH

Featuring:
• Hongming CHEN, Ph.D., Professor & Principal Investigator, Guangzhou Regenerative Medicine and Health, Guangdong Laboratory (GRMH-GDL)
• Tao GUO, Ph.D., VP & Head, International Discovery Service Unit, WuXi AppTec
• Guido Lanza, President & CEO, Numerate Inc.
• Pek Lum, Ph.D., CEO, Auransa Inc.
• Alex Zhavoronkov, Ph.D., CEO, Insilico Medicine Inc.

11:40 AM  to  12:20 PM
Scaling Up China
Ballroom 1 (5th Floor)
Biotech's history is clear: It's been easy to start companies. The challenge is to build sustainable businesses. China has created a small group of bellwethers. The question is, what is their path forward? And what are the options for new start-ups that will follow them and build out the ecosystem? Have the winners in the West created the template to follow, or are there new China-centric approaches to business-building that will create bigger successes, faster?

Session Chair:
• Debra Yu, M.D., President & Chief Business Officer, LianBio

Featuring:
• Ronnie Ede, CFO, Innovent Biologics Inc.
• Nisa Leung, Managing Partner, Qiming Ventures
• Bin LI, Ph.D., CEO & Chief Investment Officer, Lake Bleu Capital
• Jonathan Yining Zhao, Ph.D., Executive Chairman, Transcenta Holding Ltd.
• Zhenping ZHU, Ph.D., President of R&D and Chief Scientific Officer, 3SBio Inc.

12:10 PM  to  1:10 AM
Boxed Lunch & Networking
Grab a boxed lunch and network with China Summit delegates.
1:00 PM  to  2:00 PM
Presenting Companies: Belgium Biotech Track (Session 2)
Ballroom 2 (5th Floor)
Hosted by AGIO Capital and Business Solutions, Flanders Investment and Trade, AWEX, BioCentury and BayHelix

1:00pm-1:15pm Octimet Oncology N.V.

1:15pm-1:30pm eTheRNA immunotherapies N.V.

1:30pm-1:45pm Miracor Medical S.A.

1:45pm-2:00pm Mithra Pharmaceuticals S.A. (Euronext:MITRA)


Presenting Companies: 3rd Annual Healthcare AI/Precision Medicine Showcase (Part 3)
Ballroom 3 (5th Floor)
Hosted by Insilico Medicine Inc., BioCentury and BayHelix

1pm-1:15pm Insilico Medicine Inc.

1:15pm-1:30pm LinkDoc Technology Ltd.

1:30pm-1:45pm Auransa Inc.

1:45pm-2:00pm Happy Life Tech



1:10 PM  to  2:00 PM
Hard Decisions For Oncology Drug Developers
Ballroom 1 (5th Floor)
Cancer is the great magnet for biopharma company formation and finance. But the results could be disappointing. Oncology drugs fight for smaller and smaller patient populations and their share of market will be diminished by molecular diagnostics and combination therapies that will also demand a share of the profit. What are the key decisions that oncology drug developers must make to succeed? And will Chinese companies be exempt from this reality?

Session Chair:
• Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury

Featuring:
• Laura Benjamin, Ph.D., President & CEO, Oncologie Inc.
• Thomas Dubensky, Ph.D, President & CEO, Tempest Therapeutics Inc.
• Frank Jiang, M.D., Ph.D., Chairman & CEO, CStone Pharmaceuticals Co. Ltd.
• Lewis T. "Rusty" Williams, M.D., Ph.D., CEO, Walking Fish Therapeutics, and Venture Partner, Quan Capital
• Dajun Yang, M.D., Ph.D., Chairman & CEO, Ascentage Pharma
• Frank Zhang, Ph.D., CEO, GenScript Biotech Corp., and Chairman, Legend Biotech

2:00 PM  to  2:40 PM
The Hot Spot Race
Ballroom 1 (5th Floor)
While scientific prowess is distributed throughout the U.S. and Europe, only a few locations have attracted a critical mass of talent and finance to become “Hot Spots” of biopharma innovation. Is the same story already being told in China? Where will Hot Spots rise outside of Shanghai, Beijing and Suzhou?

Session Chair:
• Stella Xu, Ph.D., Managing Director, Quan Capital

Featuring:
• Kewen JIN, M.D., Managing Partner, Serica Partners
• Jin LI, Ph.D., Chairman & CEO, HitGen Ltd.
• Andrew Wong, VP, Transactions Asia Pacific, Johnson & Johnson Innovation
• Tina Xu, VP, China Digital & Commercial Innovation, AstraZeneca Plc
• Guo-Liang Yu, Ph.D., CEO & Co-founder, Apollomics Inc.

2:05 PM  to  3:20 PM
Presenting Companies: U.K. Biotech Track (Session 3)
Ballroom 2 (5th Floor)
Hosted by BIA

2:05pm-2:20pm Vaccitech Ltd.

2:20pm-2:35pm Crescendo Biologics Ltd.

2:35pm-2:50pm Oxford Biomedica plc (LSE:OXB)

2:50pm-3:05pm Arecor Ltd.

3:05pm-3:20pm LightOx Ltd.
2:40 PM  to  3:20 PM
How To Solve China’s Talent Challenges
Ballroom 1 (5th Floor)
The shortage of top management talent is a worldwide problem, including in the U.S. To be a top player in the global ecosystem, China must not only find scarce executive leadership, but also build skills that meet global requirements for excellence in product discovery and development. How can China become a destination for the talent it needs, or can it find a different management model that leverages the best people wherever they may be?

Session Chair:
• Peter Zhang, Executive Director, Russell Reynolds Associates

Featuring:
• Jun BAO, Ph.D., CEO, Impact Therapeutics Inc.
• James Huang, Managing Partner, KPCB China, and Founding Managing Partner, Panacea Venture
• Liping LIU, Ph.D., Founder, CEO & Chief Scientific Officer, HighTide Therapeutics Inc.
• Pony LU, CEO, Visen Pharmaceuticals
• Gary Wang, VP, Human Resources, APAC & Co-Lead Global HR, BeiGene Ltd.

3:20 PM  to  3:50 PM
Afternoon Networking Break
3:30 PM  to  6:00 PM
Presenting Companies: Global Biotech Track 1 (Session 4)
Ballroom 2 (5th Floor)
Hosted by Zai Lab Ltd., BioCentury and BayHelix

3:30pm-3:45pm Zai Lab Ltd. (NASDAQ:ZLAB)

3:45pm-4pm Synaffix B.V.

4pm-4:15pm Oncologie Inc.

4:15pm-4:30pm Hookipa Pharma Inc. (NASDAQ:HOOK)

4:30pm-4:45pm Boston Pharmaceuticals Inc.

4:45pm-5pm Tracon Pharmaceuticals Inc. (NASDAQ:TCON)

5pm-5:15pm Bioshin subsidiary of Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN)

5:15pm-5:30pm Genenta Science s.r.l.

5:30pm-5:45pm CytomX Therapeutics Inc. (NASDAQ:CTMX)

5:45pm-6pm Sotio a.s.
3:50 PM  to  4:30 PM
The Manufacturing Road
Ballroom 1 (5th Floor)
For China to stand alongside the world’s leaders in biopharma innovation, it requires local manufacturing that meets global standards and delivers affordably at scale. China’s new Marketing Authorization Holder policy could create a level playing field for Chinese innovators to access manufacturers like Western biotechs. What remains to be answered is how China will create a global brand in quality that will stimulate demand for its first-generation biologics and help validate its next-generation of manufacturing innovators in new modalities like cell therapy.

Session Chair:
• Dianna Qian, Partner, Pivotal Bioventure China

Featuring:
• Carl Firth, Ph.D., Founder & CEO, Aslan Pharmaceuticals Ltd.
• Wei KANG, VP, Strategic Consulting, AUSTAR Group
• BG Rhee, Ph.D., CEO, SCM Life Sciences, and Chairman, Council for Advanced Regenerative Medicine
• Kristine Senft, VP Global Business Development & Key Account Management, Boehringer Ingelheim Biopharmaceuticals GmbH
• Yongzhong WANG, Ph.D., CEO, CMAB BioPharma Ltd.

4:30 PM  to  5:20 PM
Cross Border Strategies For China/Europe Partnerships
Ballroom 1 (5th Floor)
China investors have discovered the promise of European innovation, while Europe’s innovators have discovered the opportunities to develop drugs and diagnostics in China. But how does each side find the right partners?

Session Chairs:
• Sean Cao, Ph.D., CEO, Everest Medicines Ltd.
• Henk Joos, Ph.D., General Manager, Agio Capital & Business Solutions

Featuring:
• David Cox, Ph.D., Director, Healthcare, Panmure Gordon and Co.
• Theodora Harold, CEO, Crescendo Biologics Ltd.
• Bart Van Hooland, Founding Partner, DROIA Oncology Ventures
• Da LIU, Managing Director, CR-CP Life Science Fund
• Chengbin WU, Ph.D., Founder & CEO, EpimAb Biotherapeutics Inc.
• John Zhu, Ph.D., Partner, 6 Dimensions Capital

6:00 PM  to  10:00 PM
Gala Reception & Dinner
Ballroom 3 (5th Floor)
Hosted by CBC Group, BioCentury and BayHelix
Wednesday, November 20, 2019

7:45 AM  to  8:50 AM
Registration & Breakfast Networking
Shanghai Jing An Shangri-La (5th Floor)
Hosted by Novo Nordisk, BioCentury and BayHelix
8:50 AM  to  9:00 AM
Welcoming Remarks
• Joshua Berlin, Executive Director, BioCentury

9:00 AM  to  9:40 AM
Fireside Chat – China Inside And Out
Ballroom 1 (5th Floor)
Luke Miels, President of Global Pharmaceuticals at GlaxoSmithKline Plc, oversees more than $20 billion in sales in more than 100 markets worldwide. His career has includes serving as Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs at AstraZeneca plc and as Regional Vice President of Asia Pacific for the Pharmaceuticals Division of Roche. His views on the emergence and future of China provides the context for the second day of the Summit and its focus on “managing for domestic and global impact.”

Moderator:
• Jeff Algazy, Senior Partner, McKinsey & Co.

Featuring:
• Luke Miels, President, Global Pharmaceuticals, GlaxoSmithKline Plc

9:40 AM  to  10:30 AM
The Bridge To Innovation Report – China In The World
Ballroom 1 (5th Floor)
Insights Partner McKinsey & Co. delivers the key findings from its 6th Bridge to Innovation report, created exclusively for the China Healthcare Summit.

Session Chair:
• Tina Hou, Partner, McKinsey & Co.

10:30 AM  to  11:00 AM
Morning Networking Break
Hosted by Novo Nordisk, BioCentury and BayHelix
10:45 AM  to  12:00 PM
Presenting Companies: Korea Biotech Track (Session 5)
Ballroom 2 (5th Floor)
Hosted by KDDF (Korea Drug Development Fund), BIP focus, BioCentury and BayHelix

10:45am-11am Isu Abxis Co. Ltd. (KOSDAQ:086890)

11am-11:15am ImmuneOncia Therapeutics Inc.

11:15am-11:30am OliPass Corp. (KOSDAQ:244460)

11:30am-11:45am GeneMedicines Co. Ltd.

11:45am-12pm PharmAbcine Inc. (KOSDAQ:208340)
11:00 AM  to  12:00 PM
View From The Top – Seeing China In The Global Context
Ballroom 1 (5th Floor)
China is demanding the attention of global biopharma strategists. This panel of biopharma executives, all charged with managing from a global context, reflect on China’s growing influence and its implications for APAC, emerging markets and the world beyond.

Session Chair:
• Martin Dewhurst, Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice, McKinsey & Co.

Featuring:
• Alberto Colzi, President International, Japan, Emerging Markets & Australia, AbbVie Inc.
• Fabio Landazabal, M.D., SVP & Head of Emerging Markets, GlaxoSmithKline plc
• Ai Hua Ong, Group Chairman, Janssen Asia Pacific
• Penny Wan, VP & Regional General Manager, JAPAC, Amgen Inc.
• Leon Wang, EVP, International Region & China President, AstraZeneca

12:00 PM  to  1:30 PM
10th Annual Bayhelix Awards Lunch Banquet
Ballroom 3 (5th Floor)
For the 10th year, BayHelix celebrates outstanding individuals and companies for achievements and contributions to China’s healthcare ecosystem: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

Emcee:
• Victor Shi, Ph.D., Chairman, BayHelix, and CEO, Adicon Clinical Laboratories Inc.

1:30 PM  to  2:30 PM
View From The Top – China Gm Perspectives
Ballroom 1 (5th Floor)
Biopharma businesses in China are at a new crossroads, with innovation taking off and mature brands under the pressure of volume-based purchasing policies. In the Summit's 6th annual GM plenary, China Country presidents share their views on where the market is headed and how they plan to address today's major uncertainties.

Session Chair:
• Jake Henry, Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice, McKinsey & Co.

Featuring:
• Julio Gay-Ger, President & General Manager, China, Eli Lilly and Co.
• Christian Hogg, Executive Director & CEO, Chi-Med (Hutchison China MediTech Ltd.)
• Pius S. Hornstein, Ph.D., Country Chair & General Manager, Sanofi China
• Joseph Romanelli, President, MSD China
1:30 PM  to  4:00 PM
Presenting Companies: Global Biotech Track 2 (Session 6)
Ballroom 2 (5th Floor)
Hosted by Zai Lab Ltd., BioCentury and BayHelix

1:30pm-1:45pm Summit Therapeutics plc (NASDAQ:SMMT)

1:45pm-2pm Tempest Therapeutics Inc.

2:00pm-2:15pm Anima Biotech Inc.

2:15pm-2:30pm Aptorum Group Ltd. (NASDAQ:APM)

2:30pm-2:45pm Retrogenix Ltd.

2:45pm-3:00pm EryDel S.p.A.

3:00-3:15pm DotBio Pte. Ltd.

3:15pm-3:30pm Elpiscience Biopharma Ltd.

3:30pm-3:45pm Bioncotech Therapeutics S.L.

3:45pm-4:00pm Q3 Medical Devices Ltd.

2:30 PM  to  3:20 PM
Capital Markets Showcase – Follow The Money
Ballroom 1 (5th Floor)
The first great wave of Chinese investor money has joined the biopharma ecosystem in the West, while the first wave of innovator biotechs has tapped the Chinese capital markets. The Summit’s 2nd Capital Markets Showcase asks what happens next? Are Chinese fund flows sustainable, and what needs to happen for Hong Kong and Shanghai to become destinations for global fundraisers?

Session Chair:
• Vijay Karwal, Head of Healthcare Investment Banking, Asia ex-Japan, Nomura

Featuring:
• Michael Chan, Head, International Issuer Services, Hong Kong Exchanges and Clearing Ltd.
• James Lin, Partner, Davis Polk
• Xianping LU, Ph.D., Founder, Chairman & CEO, Shenzhen Chipscreen Biosciences Ltd.
• Ning LI, Ph.D., Executive Director, CEO & GM, Shanghai Junshi Biosciences Co. Ltd.
• Steven Powell, Ph.D., CEO, eTheRNA immunotherapies N.V.
• Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascletis Pharma

3:20 PM  to  4:00 PM
Closing Plenary: Speaking For China’s Innovators
Ballroom 1 (5th Floor)
China’s biopharma innovators face enormous tasks: They must compete against global competition and communicate to China’s policy makers what they need to succeed. SONG Rulin, Executive President of PhIRDA, the China Pharmaceutical Innovation and Research Development Association, and KANG Wei, Managing Director of RDPAC, the R&D-Based Pharmaceutical Association Committee, discuss how their members are addressing these twin challenges in a discussion with Kevin Li of LYZZ Capital.

Moderator:
• Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital

Featuring:
• Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee)
• Ruilin SONG, Executive President, PhIRDA (China Pharmaceutical Innovation and Research Development Association)
4:00 PM  to  4:30 PM
Closing Reception – Last Call For Networking
Shanghai Jing An Shangri-La (5th Floor)
Join BioCentury, BayHelix and McKinsey & Co. for a final round of networking with China Summit delegates.
PRESENTERS

The 6th China Healthcare Summit will feature Road Show presentations to showcase private and public biotechs from China, Asia and the West. This will be a unique opportunity for companies to present in Shanghai to top China investors and biopharma CEOs, as well as domestic and multinational pharma licensing executives.

Presenting Companies are hand-picked by BioCentury and BayHelix based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science.

For information on becoming a Presenting Company, please email Josh Berlin.

  • AffaMed Therapeutics
  • Anima Biotech Inc.
  • Aptorum Group Ltd.
  • Arecor Ltd.
  • Auransa Inc.
  • Beigene
  • Bioncotech Therapeutics S.L.
  • BioShin
  • Boston Pharma
  • Crescendo
  • CytomX Therapeutics Inc.
  • DotBio Pte. Ltd.
  • Elpiscience Biopharmaceuticals Co Ltd
  • EOC
  • EryDel S.p.A.
  • eTheRNA immunotherapies N.V.
  • GeneMedicine Co. Ltd.
  • Genenta Science
  • Happy Life Technology (HLT) Group
  • Hookipa Pharma Inc.
  • Hua Medicine
  • ImmuneOncia Therapeutics Inc.
  • Impact Therapeutics Inc.
  • Insilico Medicine Inc
  • ISU Abxis Co. Ltd.
  • Lightox Ltd.
  • LinkDoc Technology Ltd.
  • Miracor Medical S.A.
  • Mithra Pharmaceuticals S.A.
  • Octimet Oncology Nv
  • OliPass Corp.
  • Oncologie Inc.
  • Oxford Biomedica
  • PharmAbcine Inc.
  • Q3 Medical Devices Ltd.
  • Retrogenix Ltd.
  • Sotio a.s.
  • Summit Therapeutics Plc
  • Synaffix B.V.
  • Tempest Therapeutics Inc.
  • Tracon Pharmaceuticals Inc.
  • Transcenta Holding Ltd.
  • Vaccitech Ltd.
  • Yisheng Biopharma Co. Ltd.
  • Zai Lab
  • Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
SPONSORS

The importance of the China Healthcare Summit is demonstrated by the commitment from its collaborators and supporting organizations. For information on sponsorship opportunities, please email Josh Berlin at BioCentury.

INSIGHTS PARTNER

  • {title}

CHINA BIOTECH TRACK HOST

  • {title}

GLOBAL BIOTECH TRACK HOST

  • {title}

U.K. BIOTECH TRACK HOST

  • {title}

KOREA BIOTECH TRACK HOSTS

  • {title}
  • {title}

BELGIUM BIOTECH TRACK HOSTS

  • {title}
  • {title}
  • {title}

AI/PRECISION MEDICINE TRACK HOST

  • {title}

CEO STRATEGIC BOOT CAMP HOSTS

  • {title}
  • {title}
  • {title}

TALENTS PARTNER

  • {title}

SPONSORS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

NETWORKING HOST SPONSORS

  • {title}
  • {title}

SUPPORTING ORGANIZATIONS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

PARTNER EVENT

  • {title}

SPEAKERS
Jeffrey Algazy

Jeffrey Algazy

Senior Partner
McKinsey & Co.
Jun BAO, Ph.D.

Jun BAO, Ph.D.

President & CEO
Impact Therapeutics
Yong Ben, M.D.

Yong Ben, M.D.

CMO, Medical Officer, Immuno-oncology
BeiGene Ltd.
Laura Benjamin, Ph.D.

Laura Benjamin, Ph.D.

President & CEO
Oncologie Inc.
Joshua Berlin

Joshua Berlin

Executive Director, New Ventures
BioCentury
Karen Bernstein, Ph.D.

Karen Bernstein, Ph.D.

Chairman
BioCentury
Sean Cao, Ph.D.

Sean Cao, Ph.D.

CEO
Everest Medicines
Michael Chan

Michael Chan

Head, International Issuer Services
Hong Kong Exchanges and Clearing Ltd.
Hongming CHEN, Ph.D.

Hongming CHEN, Ph.D.

Professor & Principal Investigator
Guangzhou Regenerative Medicine and Health
Lanhee Chen, Ph.D.

Lanhee Chen, Ph.D.

Senior Counselor
Brunswick LLP
Li CHEN, Ph.D.

Li CHEN, Ph.D.

Founder & CEO
Hua Medicine Ltd.
Tony Chen, J.D.

Tony Chen, J.D.

Partner
Jones Day
Yuzhong CHEN, M.D.

Yuzhong CHEN, M.D.

Chief Medical Officer & VP
Airdoc
Yongshun CHENG

Yongshun CHENG

Director
Beijing Intellectual Property Institute, and former Senior Judge, IP Division, Beijing High People’s Court
Alberto Colzi

Alberto Colzi

President International, Japan, Emerging Markets & Australia
AbbVie Inc.
David Cox, Ph.D.

David Cox, Ph.D.

Director, Healthcare
Panmure Gordon and Co.
Joe Damond

Joe Damond

EVP, International Affairs
BIO (Biotechnology Innovation Organization)
Martin Dewhurst

Martin Dewhurst

Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice
McKinsey & Co.
Meng DING

Meng DING

Partner
Sidley Austin LLP
Thomas Dubensky, Ph.D

Thomas Dubensky, Ph.D

President & CEO
Tempest Therapeutics Inc.
Ronnie Ede

Ronnie Ede

CFO
Innovent Biologics Inc.
Carl Firth, Ph.D.

Carl Firth, Ph.D.

Founder & CEO
Aslan Pharmaceuticals Ltd.
Simone Fishburn, Ph.D.

Simone Fishburn, Ph.D.

Vice President and Executive Editor
BioCentury
David Flores

David Flores

President & CEO
BioCentury
Tao Fu

Tao Fu

President & COO
Zai Lab
Julio Gay-Ger

Julio Gay-Ger

President & General Manager, Lilly China
Eli Lilly and Co.
Tao GUO, Ph.D.

Tao GUO, Ph.D.

VP & Head, International Discovery Service Unit
WuXi AppTec
Wenyu Guo, M.D.

Wenyu Guo, M.D.

VP, Clinical Operations
CStone Pharmaceuticals Co. Ltd.
Yiming HAO

Yiming HAO

General Manager, Innovative Commercialization Solutions
HLT
Theodora Harold

Theodora Harold

CEO
Crescendo Biologics Ltd.
Jake Henry

Jake Henry

Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice
McKinsey & Co.
Christian Hogg

Christian Hogg

Executive Director & CEO
Hutchison China MediTech Ltd.
Irene Hong

Irene Hong

Founding Partner
CEC Capital
Pius S. Hornstein, Ph.D.

Pius S. Hornstein, Ph.D.

Country Chair & General Manager
Sanofi China
Tina Hou

Tina Hou

Partner, Shanghai
McKinsey & Co.
James Huang

James Huang

Managing Partner
KPCB China, and Founding Managing Partner, Panacea Venture
Min Irwin, Ph.D.

Min Irwin, Ph.D.

CEO
Reistone Biopharma Co. Ltd.
Ruchun JI

Ruchun JI

Partner
Sidley Austin LLP
Frank Jiang, M.D., Ph.D.

Frank Jiang, M.D., Ph.D.

CEO
CStone Pharmaceuticals
Kewen JIN, M.D.

Kewen JIN, M.D.

Managing Partner
Serica Capital
Henk Joos, Ph.D.

Henk Joos, Ph.D.

General Manager
Agio Capital & Business Solutions
Wei KANG

Wei KANG

VP, Strategic Consulting
AUSTAR Group
Wei KANG

Wei KANG

Managing Director
RDPAC (R&D-Based Pharmaceutical Association Committee)
Vijay P. Karwal

Vijay P. Karwal

Managing Director, Head of Healthcare Investment Banking, Asia ex-Japan
Nomura
Fabio Landazabal

Fabio Landazabal

Senior Vice President & Head of Pharmaceuticals, Emerging Markets and General Manager, China Pharmaceutical
GlaxoSmithKline plc
Guido Lanza

Guido Lanza

CEO
Numerate Inc.
Franck Le Deu

Franck Le Deu

Senior Partner & Head of Greater China Healthcare Practice
McKinsey & Co.
Nisa Leung

Nisa Leung

Managing Partner
Qiming Venture Partners
Bin LI, Ph.D.

Bin LI, Ph.D.

CIO and CEO
Lake Bleu Capital
Derrick Li

Derrick Li

Head of Strategy & Investor Relations
Cellular Biomedicine Group
Helen Qinghong LI, M.D.

Helen Qinghong LI, M.D.

Head, Medical Quality Assurance, China
Pfizer Inc.
Jin LI, Ph.D.

Jin LI, Ph.D.

Chairman & CEO
HitGen Ltd.
Judith Li

Judith Li

Partner
Lilly Asia Ventures
Kevin Li, Ph.D.

Kevin Li, Ph.D.

Co-Founder & Managing Partner
LYZZ Capital
Ning LI, Ph.D.

Ning LI, Ph.D.

Executive Director, CEO & GM
Shanghai Junshi Biosciences Co. Ltd.
James Lin

James Lin

Partner
Davis Polk
Da Liu

Da Liu

Managing Director
CR-CP Life Science Fund 
Liping LIU, Ph.D.

Liping LIU, Ph.D.

Founder, CEO & Chief Scientific Officer
HighTide Therapeutics Inc.
Yi LIU

Yi LIU

VP, Clinical Science & Medical Affairs
dMed Biopharmaceutical Co. Ltd.
Joseph Chi-Lun Lo

Joseph Chi-Lun Lo

Partner
Brunswick Group LLP
Chris Lu, Ph.D.

Chris Lu, Ph.D.

Founder & CEO
Laekna Therapeutics Shanghai Co. Ltd.
Hongtao LU, Ph.D.

Hongtao LU, Ph.D.

Co-Founder, Chief Scientific Officer & Director
Elpiscience Biopharmaceuticals Co. Ltd.
Pony LU

Pony LU

CEO
Visen Pharmaceuticals
Xianping LU, Ph.D.

Xianping LU, Ph.D.

Founder & CEO
Shenzhen Chipscreen Biosciences Ltd.
Pek Lum, Ph.D.

Pek Lum, Ph.D.

Co-founder and CEO
Auransa Inc.
James Mendenhall

James Mendenhall

Partner
Sidley Austin LLP and former General Counsel, Office of the United States Trade Representative
Luke Miels

Luke Miels

President, Global Pharmaceuticals
GSK
St. John Moore

St. John Moore

Partner & Head of Beijing
Brunswick Group LLP
Ai Hua Ong

Ai Hua Ong

Company Group Chairman
Janssen Asia Pacific
Steven Powell, Ph.D.

Steven Powell, Ph.D.

CEO
eTheRNA immunotherapies N.V.
Dianna Qian

Dianna Qian

Partner
Pivotal Bioventure China
Dongxu QIU, Ph.D.

Dongxu QIU, Ph.D.

Co-Founder & Executive VP, Strategy and Business Development
CanSino Biologics Inc.
Randall Rader

Randall Rader

Principal
The Radar Group, and former Chief Judge, U.S. Court of Appeals for the Federal Circuit
B.G. Rhee

B.G. Rhee

CEO
SCM Life Sciences, and Chairman, Council for Advanced Regenerative Medicine
Joseph Romanelli

Joseph Romanelli

President, MSD China
Merck & Co. Inc.
Graziano Seghezzi

Graziano Seghezzi

Managing Partner
Sofinnova Partners
Kristine Senft

Kristine Senft

VP Global Business Development & Key Account Management
Boehringer Ingelheim Biopharmaceuticals GmbH
Joan Shen, M.D., Ph.D.

Joan Shen, M.D., Ph.D.

CEO
I-Mab Biopharma Co. Ltd.
Jun SHI, M.D.

Jun SHI, M.D.

SVP, Early Development & Clinical Pharmacology
dMed Biopharmaceutical Co. Ltd.
Victor Shi, Ph.D.

Victor Shi, Ph.D.

Chairman
BayHelix, and CEO, Adicon Clinical Laboratories Inc.
Ruilin Song

Ruilin Song

Executive President
PhIRDA (China Pharmaceutical Innovation and Research Development Association)
Sophie Sun

Sophie Sun

Managing Director, Innovation Hub China & VP, Strategy and Transformation, China
Merck Holding (China) Co. Ltd.
Lingshi Tan, Ph.D.

Lingshi Tan, Ph.D.

Founder & CEO
dMed Biopharmaceutical Co. Ltd.
Lei XIAO, Ph.D.

Lei XIAO, Ph.D.

Chairman, CEO & Chief Scientific Officer
Innovative Cellular Therapeutics Co. Ltd.
Stella Xu, Ph.D.

Stella Xu, Ph.D.

Managing Director
Quan Capital
Angela Yan

Angela Yan

SVP, Regulatory Affairs & Strategy
dMed Biopharmaceutical Co. Ltd.
Steve Yang, Ph.D.

Steve Yang, Ph.D.

EVP, Chief Business Officer
WuXi Apptec
Bart Van Hooland

Bart Van Hooland

Founding Partner
DROIA Oncology Ventures
Penny Wan

Penny Wan

VP & Regional General Manager, JAPAC
Amgen Inc.
Gary Wang

Gary Wang

VP, Human Resources, APAC & Co-Lead Global HR
BeiGene Ltd.
Leon Wang

Leon Wang

EVP, International Region & China President
AstraZeneca
Yongzhong WANG, Ph.D.

Yongzhong WANG, Ph.D.

CEO
CMAB BioPharma Ltd.
Zaiqi WANG, Ph.D.

Zaiqi WANG, Ph.D.

Founder & CEO
InxMed Shanghai
Lewis T. Rusty Williams, Ph.D.

Lewis T. Rusty Williams, Ph.D.

Venture Partner
Quan Capital
Andrew Wong

Andrew Wong

VP, Transactions Asia Pacific
Johnson & Johnson Innovation
Chengbin WU, Ph.D.

Chengbin WU, Ph.D.

Founder & CEO
EpimAb Biotherapeutics Inc.
Jinzi Wu, Ph.D.

Jinzi Wu, Ph.D.

Founder, Chairman & CEO
Ascletis Pharma Inc.
Xiaobin WU, Ph.D.

Xiaobin WU, Ph.D.

General Manager of China & President
BeiGene Ltd.
Tina Xu

Tina Xu

VP, China Digital & Commercial Innovation
AstraZeneca plc
Dajun Yang, M.D., Ph.D.

Dajun Yang, M.D., Ph.D.

Chairman & CEO
Ascentage Pharma
Peiyng Yao

Peiyng Yao

Executive Director, Quality Assurance
dMed Biopharmaceutical Co. Ltd.
ZHOU Yi

ZHOU Yi

Director
Brunswick Group LLP
Debra Yu, M.D.

Debra Yu, M.D.

President & Chief Business Officer
LianBio
Guo-Liang Yu, Ph.D.

Guo-Liang Yu, Ph.D.

CEO & Co-founder
Apollomics Inc.
Eric Zhang, Ph.D.

Eric Zhang, Ph.D.

VP, Regulatory Affairs & Strategy
dMed Biopharmaceutical Co. Ltd.
Frank Zhang, Ph.D.

Frank Zhang, Ph.D.

CEO
GenScript Biotech Corp., and Chairman, Legend Biotech
Peter Zhang

Peter Zhang

Executive Director
Russell Reynolds Associates
Tony Zhang

Tony Zhang

Founder & CEO
LinkDoc Technology (Beijing) Co.
Weiyi ZHANG

Weiyi ZHANG

Director, External Innovation China
Boehringer Ingelheim GmbH
Jonathan Zhao, Ph.D.

Jonathan Zhao, Ph.D.

co-founder & Executive Chairman
Transcenta Holding Ltd.
Alex Zhavoronkov, Ph.D.

Alex Zhavoronkov, Ph.D.

CEO
Insilico Medicine Inc.
John Zhu, Ph.D.

John Zhu, Ph.D.

Partner
6 Dimensions Capital
Zhenping ZHU, Ph.D.

Zhenping ZHU, Ph.D.

President of R&D and Chief Scientific Officer
3SBio Inc.
Hao ZOU, Ph.D.

Hao ZOU, Ph.D.

CEO
Tsimage Technology, and Director, Center for Medical Imaging and Health, Tsinghua University
ORGANIZING COMMITTEE
Jun BAO, Ph.D.

Jun BAO, Ph.D.

President & CEO
Impact Therapeutics
Yong Ben, M.D.

Yong Ben, M.D.

CMO, Medical Officer, Immuno-oncology
BeiGene Ltd.
Joshua Berlin

Joshua Berlin

Executive Director, New Ventures
BioCentury
Karen Bernstein, Ph.D.

Karen Bernstein, Ph.D.

Chairman
BioCentury
Tony Chen, J.D.

Tony Chen, J.D.

Partner
Jones Day
Simone Fishburn, Ph.D.

Simone Fishburn, Ph.D.

Vice President and Executive Editor
BioCentury
David Flores

David Flores

President & CEO
BioCentury
Lin Sun-Hoffman Ph.D., J.D.

Lin Sun-Hoffman Ph.D., J.D.

Partner
Liu, Zheng, Chen & Hoffman LLP
Kewen JIN, M.D.

Kewen JIN, M.D.

Managing Partner
Serica Capital
Franck Le Deu

Franck Le Deu

Senior Partner & Head of Greater China Healthcare Practice
McKinsey & Co.
Bin LI, Ph.D.

Bin LI, Ph.D.

CIO and CEO
Lake Bleu Capital
Jon Liong

Jon Liong

Managing Partner
Lychee Group
Wendy Pan, Ph.D.

Wendy Pan, Ph.D.

Partner
Goodwin Procter
Victor Shi, Ph.D.

Victor Shi, Ph.D.

Chairman
BayHelix, and CEO, Adicon Clinical Laboratories Inc.
Steve Yang, Ph.D.

Steve Yang, Ph.D.

EVP, Chief Business Officer
WuXi Apptec
Debra Yu, M.D.

Debra Yu, M.D.

President & Chief Business Officer
LianBio
Dan Zhang, M.D.

Dan Zhang, M.D.

Chairman
Fountain Medical Development Ltd.
Jimmy Zhang, Ph.D.

Jimmy Zhang, Ph.D.

Venture Partner
Lilly Asia Ventures
Wei Zhang, Ph.D., M.D.

Wei Zhang, Ph.D., M.D.

SVP & Chief Strategy Officer
WuXi AppTec
AWARD WINNERS

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. This year, BayHelix and BioCentury will jointly host the 6th China Healthcare Summit (November 18-20, Shanghai), and present the awards in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.